Pharsight

1. Cabometyx patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP12704492A	2022-08-01	STADA Arzneimittel AG	Revoked
EP11740764A	2022-07-13	Generics (U.K.) Limited	Granted and Under Opposition
EP11740764A	2022-07-12	STADA Arzneimittel AG	Granted and Under Opposition
EP11740764A	2022-07-12	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP10701175A	2013-12-06	Ladendorf, Oliver	Patent maintained as amended
EP10701175A	2013-12-05	Gallafent, Alison	Patent maintained as amended
EP10701175A	2013-12-05	Actavis Group PTC ehf	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7579473	EXELIXIS INC	c-Met modulators and methods of use	Aug, 2026 (2 years from now)
US11091439	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Jan, 2030 (6 years from now)
US8877776	EXELIXIS INC	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Oct, 2030 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284	EXELIXIS INC	C-met modulators and method of use	Sep, 2024 (11 months from now)
US11098015	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (6 years from now)
US11091440	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (6 years from now)
US10039757	EXELIXIS INC	C-Met modulator pharmaceutical compositions	Jul, 2031 (7 years from now)
US10034873	EXELIXIS INC	C-met modulator pharmaceutical compositions	Jul, 2031 (7 years from now)
US11298349	EXELIXIS INC	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb, 2032 (8 years from now)
US9724342	EXELIXIS INC	C-met modulator pharmaceutical compositions	Jul, 2033 (9 years from now)
US11141413	EXELIXIS INC	Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate	Apr, 2037 (13 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 17, 2028
New Indication (I)	Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma; Treatment of d...

Dosage: TABLET;ORAL